To evaluate ixekizumab , an anti-interleukin-@A ( anti-IL-@A ) monoclonal antibody , in @ populations of rheumatoid arthritis ( RA ) patients : biologics-naive patients and patients with an inadequate response to tumor necrosis factor ( TNF ) inhibitors .